



Convertible notes extension and additional funding

Highlights

- **Convertible noteholders agree to maturity date extension**
- **Additional loan funding secured**

Sydney, 23 September 2025: Innovative biotech company **Noxopharm Limited (ASX:NOX)** is pleased to announce that its existing convertible noteholders (with a total aggregate note face value of \$2,600,000) have approved the extension of the maturity date of their convertible notes to 2 January 2027, (subject to shareholder approval at the upcoming AGM).

This will allow the company to access rebate funds of approximately \$2,800,000 from the Australian Federal Government's Research and Development Tax Incentive Scheme for the financial year ended 30 June 2025, in order to provide additional ongoing working capital.

The noteholders will be paid accrued interest of \$327,000 in aggregate on the convertible notes in cash for the period ending 2 January 2026, with the interest accruing from 2 January 2026 capitalised daily until maturity.

As an incentive for their ongoing financial support, the noteholders will be granted 520,000 additional unlisted options, allocated in the same manner as the original options attached to the convertible notes. These unlisted options are on the same terms as the original options granted to the noteholders – exercise price \$0.1488, expiring 10 September 2027.

The other terms and conditions of the convertible notes remain unchanged.

In addition, the company has entered into an unsecured loan agreement with 4F Investments Pty Limited (an entity owned and controlled by Noxopharm Chairman Mr Fred Bart). 4F Investments will provide a \$1,250,000 unsecured loan to Noxopharm, and interest will be payable at 12% p.a. on the loan capitalised daily until maturity. The interest rate payable on the unsecured loan is the same rate payable to the noteholders on the notes. The funds from the loan will be used for Noxopharm's ongoing working capital requirements.

The intention is that this unsecured loan facility will be rolled into a convertible note if approved by shareholders at the upcoming AGM, on the same terms and conditions as the existing notes on issue (with the exception that it will be unsecured), including the grant of 250,000 unlisted options, exercise price \$0.1488, expiring 10 September 2027. This will align 4F Investments financially with the existing noteholders, and the existing noteholders will not be financially disadvantaged by this arrangement. If shareholder approval is not obtained at the upcoming AGM, the unsecured loan facility will remain in place.

Noxopharm would like to thank 4F Investments and the convertible noteholders for their ongoing financial support.

For personal use only

-ENDS-

About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian clinical-stage biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Sofra™ (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma™ (oncology).

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Julian Elliott

M: 0425 840 071

E: julian.elliott@noxopharm.com

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@automicgroup.com.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.